79255127 - FREELINE

Information

  • Trademark
  • 79255127
  • Serial Number
    79255127
  • Registration Number
    5999142
  • Filing Date
    November 23, 2018
    5 years ago
  • Registration Date
    March 03, 2020
    4 years ago
  • Transaction Date
    February 06, 2023
    a year ago
  • Status Date
    March 03, 2020
    4 years ago
  • Published for Opposition Date
    December 17, 2019
    4 years ago
  • Location Date
    March 03, 2020
    4 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    BUCHANAN WILL, NORA
  • Attorney Docket Number
    0641296
    Attorney Name
    Samantha M. Quimby
    Law Office Assigned Location Code
    M70
  • Owners
Mark Drawing Code
4000
Mark Identification
FREELINE
Case File Statements
  • GS0051: Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases
  • PM0001: FREE LINE
Case File Event Statements
  • 2/6/2023 - a year ago
    25 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH
  • 8/15/2022 - a year ago
    24 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 7/24/2020 - 3 years ago
    23 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 7/8/2020 - 3 years ago
    22 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 7/8/2020 - 3 years ago
    21 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 6/3/2020 - 4 years ago
    20 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 3/3/2020 - 4 years ago
    19 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 12/17/2019 - 4 years ago
    18 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/17/2019 - 4 years ago
    17 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 11/27/2019 - 4 years ago
    16 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 11/12/2019 - 4 years ago
    15 - ASSIGNED TO LIE Type: ALIE
  • 11/7/2019 - 4 years ago
    14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 11/6/2019 - 4 years ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/6/2019 - 4 years ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/6/2019 - 4 years ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 6/14/2019 - 5 years ago
    10 - REFUSAL PROCESSED BY IB Type: RFNT
  • 5/8/2019 - 5 years ago
    9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 5/7/2019 - 5 years ago
    8 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 4/17/2019 - 5 years ago
    7 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 4/16/2019 - 5 years ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 4/2/2019 - 5 years ago
    5 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 3/27/2019 - 5 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 3/27/2019 - 5 years ago
    3 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 3/25/2019 - 5 years ago
    2 - LIMITATION FROM ORIGINAL APPLICATION ENTERED Type: LIMI
  • 3/21/2019 - 5 years ago
    1 - SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB Type: SDRC